Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Bayer Acquires Two Prescription Dermatology Product Lines From U.S. Based SkinMedica

By Pharmaceutical Processing | September 2, 2009

Intendis GmbH, which is part of Bayer HealthCare,has signed an agreement to acquire two prescription dermatology product linesfrom SkinMedica, Inc., a dermatology company based in Carlsbad, CA, USA.Both Desonate(R) and NeoBenz(R) Micro are currently marketed in the U.S.by SkinMedica, Inc. Under the transaction, which is still subject to thenecessary regulatory approvals, Intendis will acquire all commercial rights,including assigned contracts and intellectual property related to the twoproduct lines. The deal is expected to close in the Fall of 2009. “We are currently seeing solid growth of our existing portfolio ofprescription dermatologicals in the U.S. With the addition of these twohigh-quality product lines we expect to build on this dynamic and tosubstantially strengthen our presence in this key strategic business,” statedMarc Lafeuille, President and CEO of the Intendis Group. In 2008, the companygrew by 18.7% on a currency-adjusted basis in the U.S. Desonate(R) is a low potency topical corticosteroid for the treatment ofmild to moderate atopic dermatitis, an inflammatory skin disease. Formulatedin a waterbased Hydrogel vehicle, it is indicated for patients as young as 3months. NeoBenz(R) Micro is a benzoyl peroxide medication for the treatmentof mild to moderate acne vulgaris. Its special formulation allows for agradual release of the active ingredient which allows for an effectivetreatment with only low irritation. “We are pleased that this agreement with Intendis will allow us to devoteinvestments to continued growth of our remaining dermatology business,” saidMary Fisher, President and CEO of SkinMedica. “We look forward to expandingour pipeline of innovative products for the improvement of skin appearanceand the treatment of dermatologic conditions.”

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE